Aegerion Pharmaceuticals Announces Fourth-Quarter and Year-End 2012 Financial Results
06 mars 2013 07h00 HE
|
Aegerion Pharmaceuticals, Inc.
CAMBRIDGE, Mass., March 6, 2013 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative,...
Aegerion Pharmaceuticals Observes Rare Disease Day
28 févr. 2013 08h00 HE
|
Aegerion Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Feb. 28, 2013 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), an emerging biopharmaceutical company focused on the development and commercialization of novel...
Aegerion Pharmaceuticals Announces Key Business and Financial Objectives for 2013 as the Company Prepares for U.S. Launch of JUXTAPID(TM) (lomitapide) Capsules
07 janv. 2013 07h00 HE
|
Aegerion Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Jan. 7, 2013 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative,...
FDA Approves Aegerion Pharmaceuticals' JUXTAPID(TM) (lomitapide) Capsules for Homozygous Familial Hypercholesterolemia (HoFH)
24 déc. 2012 07h00 HE
|
Aegerion Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Dec. 24, 2012 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of novel, life-altering...
Aegerion Pharmaceuticals Announces Participation at Wells Fargo Securities 2012 Healthcare Conference
13 juin 2012 08h00 HE
|
Aegerion Pharmaceuticals, Inc.
CAMBRIDGE, Mass., June 13, 2012 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), an emerging biopharmaceutical company focused on the development and commercialization of novel...
Aegerion Pharmaceuticals Announces Participation at Jefferies 2012 Global Healthcare Conference
30 mai 2012 08h00 HE
|
Aegerion Pharmaceuticals, Inc.
CAMBRIDGE, Mass., May 30, 2012 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), an emerging biopharmaceutical company focused on the development and commercialization of novel...
Aegerion Pharmaceuticals Announces Oral Presentation of Phase III Lomitapide Data at European Atherosclerosis Society Conference
29 mai 2012 08h00 HE
|
Aegerion Pharmaceuticals, Inc.
CAMBRIDGE, Mass., May 29, 2012 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), an emerging biopharmaceutical company focused on the development and commercialization of novel...
Aegerion Pharmaceuticals Announces First Quarter 2012 Financial Results
01 mai 2012 07h00 HE
|
Aegerion Pharmaceuticals, Inc.
CAMBRIDGE, Mass., May 1, 2012 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), an emerging biopharmaceutical company focused on the development and commercialization of novel...
Aegerion Pharmaceuticals Announces FDA Acceptance of New Drug Application for Review
30 avr. 2012 08h00 HE
|
Aegerion Pharmaceuticals, Inc.
CAMBRIDGE, Mass., April 30, 2012 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), an emerging biopharmaceutical company focused on the development and commercialization of novel...
Aegerion Pharmaceuticals Announces EMA Acceptance for Review of Marketing Authorization Application for Lomitapide
20 mars 2012 07h00 HE
|
Aegerion Pharmaceuticals, Inc.
CAMBRIDGE, Mass., March 20, 2012 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), an emerging biopharmaceutical company focused on the development and commercialization of novel...